Cardiovascular Today—June 4, 2026

LucidQuest

7 hours ago

This week’s Cardiovascular update highlights advances in coronary intervention technologies, imaging innovation, regulatory milestones, device safety monitoring, emerging noninvasive therapies, and growing evidence on climate-related cardiovascular risk.

In Today’s Newsletter

Dive deeper

🌡️ Climate change linked to rising US heat-related heart disease [1] [US • 01 Jun 2026]

https://cardiovascularnews.com/us-study-connects-climate-change-to-increasing-heat-related-heart-disease-nationally/
Context: Case Western Reserve University researchers used county-level cardiovascular, climate, and population data to project US heat-related heart disease through 2050.
Key point: The JAMA Cardiology study estimates heat-related heart disease could rise substantially by 2050, with higher burdens in lower-income states.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

⚠️ FDA flags Impella introducer kit recall after injuries [2] [US • 02 Jun 2026]

https://cardiovascularbusiness.com/topics/clinical/interventional-cardiology/fda-highlights-recall-certain-impella-introducer-kits-after-3-injuries
Context: FDA highlighted a voluntary recall affecting certain 14Fr Low Profile Introducer Kits used with Impella CP with SmartAssist.
Key point: Johnson & Johnson MedTech identified increased thrombus-formation risk, with three serious injuries reported.
Implication: Introduces competition that may affect pricing and formulary access.

🤖 Coredio CPSE wins FDA breakthrough device status [3] [US • 29 May 2026]

https://cardiovascularbusiness.com/topics/clinical/heart-failure/fda-sees-potential-new-ai-software-monitoring-heart-failure-patients
Context: Coredio’s Cardiac Performance Simulation Engine uses smartwatch and blood-pressure cuff data for heart failure hemodynamic assessment.
Key point: FDA granted breakthrough device designation and accepted CPSE into the TAP Pilot program.
Implication: May expand screening, initiation, and follow-up at scale.

🫀 SAPT after TAVR outperforms DAPT in registry analysis [4] [EU • 29 May 2026]

https://cardiovascularbusiness.com/topics/clinical/structural-heart-disease/tavr/sapt-after-tavr-linked-key-benefits-over-dapt-new-data-confirm
Context: TRITAVI registry data included more than 5,000 TAVR patients in Italy, Spain, Poland, Finland, and England from 2011–2023.
Key point: SAPT was associated with lower all-cause mortality at six and 24 months, plus fewer major bleeding events at six months, versus DAPT.
Implication: May influence prescriber choice and payer reviews pending full data.

🔎 AHA launches ATTR-CM Discovery Initiative [5] [US • 28 May 2026]

https://cardiovascularbusiness.com/topics/clinical/cardiac-amyloidosis/american-heart-association-takes-cardiac-amyloidosis-new-initiative
Context: The American Heart Association launched a three-year initiative focused on transthyretin amyloid cardiomyopathy.
Key point: The program aims to improve clinician awareness, non-biopsy diagnostic pathway use, and timely treatment.
Implication: May expand screening, initiation, and follow-up at scale.

📡 MIT ultrasound pacemaker concept avoids implants [6] [US • 02 Jun 2026]

https://cardiovascularbusiness.com/topics/patient-care/remote-patient-monitoring/new-look-pacemaker-uses-ultrasound-stimulate-heart-no-implant-required
Context: MIT engineers described a compact, wearable ultrasound-stimulation device in Nature Biomedical Engineering.
Key point: The chest-worn sticker stimulated human cardiac cells in lab experiments, with no implanted pacemaker required.
Implication: Signals pipeline investment and modality expansion.

💊 MYQORZO launches in Germany for obstructive HCM [7] [EU • 01 Jun 2026]

https://ir.cytokinetics.com/press-releases/press-release-details/2026/Cytokinetics-Launches-MYQORZO-aficamten-in-European-Union-with-First-Commercial-Availability-in-Germany/default.aspx
Context: Cytokinetics launched MYQORZO (aficamten), a cardiac myosin inhibitor, in Germany for symptomatic NYHA class II–III obstructive HCM in adults.
Key point: The Germany launch follows European Commission approval in February 2026 and prior approvals in the US and China.
Implication: May influence prescriber choice and payer reviews pending full data.

🧬 3D heart-wiring map targets congenital heart disease surgery [8] [EU • 02 Jun 2026]

https://www.esrf.fr/home/news/general/content-news/general/new-3d-map-of-the-electrical-wiring-of-the-heart-to-help-patients-with-congenital-heart-disease.html
Context: UCL and ESRF researchers used HiP-CT imaging to map the cardiac conduction system in Tetralogy of Fallot.
Key point: The first 3D map revealed altered right-ventricle electrical wiring that may help explain conduction disorders after repair.
Implication: May expand screening, initiation, and follow-up at scale.

Why it matters

Cardiovascular care is moving earlier, with more emphasis on prevention, remote monitoring, and noninvasive diagnostics.
Regulatory and recall activity around Impella keeps device safety and hospital inventory controls in focus.
Structural heart practice continues to shift toward simpler antithrombotic regimens after TAVR.
MYQORZO’s Germany launch extends the commercial rollout of cardiac myosin inhibition in obstructive HCM.
Advanced imaging, AI, and wearable technologies are converging around cardiac risk detection and procedural planning.

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🧰 See our full range of services. Discover how we can help you.

🎯 Catch up on the Top Cardiovascular news from the past two weeks, curated by the LucidQuest team.

🎬 Watch on YouTube.

FAQ

What did the Case Western Reserve University heat study project?

It projected a major increase in US heat-related heart disease by 2050, using county-level cardiovascular, climate, and population data. The source highlights higher burden in lower-income states. [1]

What products are involved in the Impella recall?

The FDA alert covers certain 14Fr Low Profile Introducer Kits used with Impella CP with SmartAssist. The article says the risk is thrombus formation and reports three serious injuries. [2]

What is Coredio’s CPSE designed to do?

CPSE is a software-only AI platform intended to estimate heart failure hemodynamics from consumer-grade smartwatch and blood-pressure cuff data under physician supervision. [3]

What did TRITAVI show about SAPT after TAVR?

In registry data, SAPT after TAVR was associated with lower all-cause mortality at six and 24 months and fewer major bleeding events at six months versus DAPT. [4]

What is the AHA ATTR-CM Discovery Initiative?

It is a three-year American Heart Association initiative to improve awareness, diagnosis, and treatment of transthyretin amyloid cardiomyopathy. [5]

Where did Cytokinetics launch MYQORZO in Europe first?

Cytokinetics announced first commercial European availability of MYQORZO (aficamten) in Germany for symptomatic obstructive HCM in adults. [7]

Entities / Keywords

Case Western Reserve University, JAMA Cardiology, heat-related heart disease, climate change, cardiovascular equity
Johnson & Johnson MedTech, Abiomed, Impella CP with SmartAssist, 14Fr Low Profile Introducer Kit, FDA recall
Coredio, Cardiac Performance Simulation Engine, CPSE, FDA breakthrough device, TAP Pilot, heart failure monitoring
TAVR, SAPT, DAPT, TRITAVI registry, JACC: Advances
American Heart Association, AHA, ATTR-CM Discovery Initiative, transthyretin amyloid cardiomyopathy, cardiac amyloidosis
Massachusetts Institute of Technology, MIT, ultrasound pacemaker, wearable cardiac stimulation
Cytokinetics, MYQORZO, aficamten, obstructive hypertrophic cardiomyopathy, oHCM, SEQUOIA-HCM
UCL, ESRF, HiP-CT, Human Organ Atlas, Tetralogy of Fallot, cardiac conduction system